drugset / Trial / NCT07239440
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control
Timeline
- Start
- 2025-11
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-2811 | Unknown | — | Oral |
| Subject | DA-2811-C | Unknown | — | Oral |
| Background | DA-2811-R1 | Unknown | — | Oral |
| Background | DA-2811-R2 | Unknown | — | Oral |